The Impact of Underlying Plaque Characteristics Following the Third-Generation Resorbable Magnesium Scaffold Implantation: An Intravascular OCT Assessment up to 12-Months.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a controlled clinical trial.

The acquired intravascular imaging data were evaluated to assess the presence of fibrous, calcific, or lipidic lesions.

Why It Was Studied

Third-generation resorbable magnesium scaffold (RMS) was developed with stronger mechanical properties and thinner struts compared to its predecessor.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

Patients enrolled in the BIOMAG-I trial and who underwent OCT imaging before and after the index procedure were included in the current analysis.

How the Study Was Run

The researchers calculated the proportions of each plaque feature per pullback and assessed their correlation with LLL obtained at 6- and 12-months follow-up.

In addition, the researchers investigated the potential impact of scaffold edge dissection and strut malapposition on in-scaffold LLL.

What Was Measured

The subject headings attached to it are Absorbable Implants, Coronary Artery Disease, Coronary Vessels, Fibrosis, Magnesium, Percutaneous Coronary Intervention and Plaque, Atherosclerotic.

The authors tagged it with the keywords bioresorbable magnesium scaffold, optical coherence tomography and plaque characteristics.

What This Means in Plain Language

This is a controlled clinical trial of Vitamin D, K2, Magnesium and Zinc.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2025 (Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.